Tuesday, September 22, 2020 11:51:24 PM
Learning53,...
Let me comment about your very good points ..
1.) Yes leronlimab seems to works very fast , within 3 days we see much improved blood tests , often before clinical improvement..
2.) vaccine is a different thing , there will always be people who do not take vaccine , or will not respond to it , and they will need treatment..
Every year many people dying due to flu globally.
3.) yes , it is a very hard for us to get a traction , but lets not forget, we not a Gilead,
but also lets not forget , that one our drug is working better then few of theirs , and our drug is without one serious side effect..imo
4.) I don't think that study for long hauler will be that long , I agree probably 28 days , so all depend how fast will be enrollment..
5.)Yes , long haulers look like a very significant market , so far no other medicine just us..
And All the monoclonal antibodies Dr Fauci and media are talking about , are ONLY antiviral , and do nothing to immunological abnormalities..
Well , they maybe very important in viral stage of this disease, but I really don't think they will do much here ..
6,) exactly , many long hauler don't show any covid disease , because it is a new disease produced by COVID , even if covid itself was very mild ...mostly if not completely it might be due to immunological changes , we see soon as studies will progress..... .
And ALL is IMO...
Let me comment about your very good points ..
1.) Yes leronlimab seems to works very fast , within 3 days we see much improved blood tests , often before clinical improvement..
2.) vaccine is a different thing , there will always be people who do not take vaccine , or will not respond to it , and they will need treatment..
Every year many people dying due to flu globally.
3.) yes , it is a very hard for us to get a traction , but lets not forget, we not a Gilead,
but also lets not forget , that one our drug is working better then few of theirs , and our drug is without one serious side effect..imo
4.) I don't think that study for long hauler will be that long , I agree probably 28 days , so all depend how fast will be enrollment..
5.)Yes , long haulers look like a very significant market , so far no other medicine just us..
And All the monoclonal antibodies Dr Fauci and media are talking about , are ONLY antiviral , and do nothing to immunological abnormalities..
Well , they maybe very important in viral stage of this disease, but I really don't think they will do much here ..
6,) exactly , many long hauler don't show any covid disease , because it is a new disease produced by COVID , even if covid itself was very mild ...mostly if not completely it might be due to immunological changes , we see soon as studies will progress..... .
And ALL is IMO...
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
